Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 692

2.

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.

Olson MR, Varga SM.

J Immunol. 2007 Oct 15;179(8):5415-24.

3.
5.

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.

Castilow EM, Olson MR, Varga SM.

Immunol Res. 2007;39(1-3):225-39. Review.

PMID:
17917067
6.
7.

Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon.

Piedra PA, Wyde PR, Castleman WL, Ambrose MW, Jewell AM, Speelman DJ, Hildreth SW.

Vaccine. 1993 Nov;11(14):1415-23.

PMID:
7508665
8.
9.

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.

Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M.

Virology. 2000 Mar 30;269(1):54-65.

12.
14.
16.

Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.

Peebles RS Jr, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS.

J Infect Dis. 2000 Sep;182(3):671-7. Epub 2000 Aug 4.

18.

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.

Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ.

Vaccine. 2007 Jul 20;25(29):5378-89. Epub 2007 May 24.

PMID:
17561317
Items per page

Supplemental Content

Write to the Help Desk